Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC

Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC is a phase 2, randomised interventional study registered as NCT07070713 by Fujian Cancer Hospital, with a registry enrolment figure of 44 participants, started 2025-07-30 and due to reach its primary completion in 2028-02-28. Interventions recorded: FOLFOXIRI + QL1706 + Bevacizumab; FOLFOX+QL1706+Cetuximab. Conditions listed: Metastatic Colorectal Cancer With Left-sided Primary Tumor; Immunotherapy. Primary outcome: Objective Response Rate. Colorectal eligibility wording from the registry: "Histologically or cytologically confirmed metastatic colorectal adenocarcinoma with the primary tumor located in the left-sided colon (from the splenic flexure to the rectum), including cecal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.